Tweet
Sci Rep. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
[Source: Scientific Report, full page: (LINK). Abstract, edited.]
Scientific Reports | Article / <ABBR>Open</ABBR>
<ABBR></ABBR>
<ABBR></ABBR>Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
Xiangguo Qiu,<SUP>1 </SUP>Jonathan Audet,<SUP>2 </SUP>Gary Wong,<SUP>2 </SUP>Lisa Fernando,<SUP>1 </SUP>Alexander Bello,<SUP>2 </SUP>St?phane Pillet,<SUP>1, 5 </SUP>Judie B. Alimonti<SUP>1, 2 </SUP>& Gary P. Kobinger<SUP>1, 2, 3, 4</SUP>
<SUP></SUP>
Journal name: Scientific Reports / Volume: 3, Article number: 3365 / DOI: doi:10.1038/srep03365
Received 11 September 2012 - Accepted 12 November 2013 - Published 28 November 2013
Abstract
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP?specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure.
Subject terms: Immunology ? Pathogens ? Ebola virus ? Virology
-
-------
Scientific Reports | Article / <ABBR>Open</ABBR>
<ABBR></ABBR>
<ABBR></ABBR>Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb
Xiangguo Qiu,<SUP>1 </SUP>Jonathan Audet,<SUP>2 </SUP>Gary Wong,<SUP>2 </SUP>Lisa Fernando,<SUP>1 </SUP>Alexander Bello,<SUP>2 </SUP>St?phane Pillet,<SUP>1, 5 </SUP>Judie B. Alimonti<SUP>1, 2 </SUP>& Gary P. Kobinger<SUP>1, 2, 3, 4</SUP>
<SUP></SUP>
Journal name: Scientific Reports / Volume: 3, Article number: 3365 / DOI: doi:10.1038/srep03365
Received 11 September 2012 - Accepted 12 November 2013 - Published 28 November 2013
Abstract
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP?specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure.
Subject terms: Immunology ? Pathogens ? Ebola virus ? Virology
-
-------